Table 2.
Clinical characteristics of the MGUS patients and their corresponding bolus and continuous infusion dosages of [13C5]-glutamine
| Patient # | Age | Sex | M-Spike | Isotype | Glutamine enrichment |
|---|---|---|---|---|---|
| MGUS #1c | 52 | F | 0.4 g/dL | IgG lambda | 5.21% |
| MGUS #2a | 65 | M | NQ; IgA, 476 mg/dL | IgA kappa | 4.78% |
| MGUS #3c | 71 | M | 1.2 g/dL | IgG lambda | 4.61% |
| MGUS #4c | 66 | M | 0.7 g/dL | IgG kappa | 5.57% |
| MGUS #5b | 69 | M | 1.4 g/dL | IgG lambda | 3.49% |
| MGUS #6 | 48 | M | 1.2 g/dL | IgG kappa | 4.90% |
| MGUS #7 | 56 | F | 1.2 g/dL | IgG kappa | 5.84% |
| MGUS #8c | 61 | F | NQ; IgG, 867 mg/dL | IgG lambda | 6.31% |
| MGUS #9c | 71 | M | NQ; kappa FLC, 47.5 mg/dL | Free kappa | 6.25% |
| MGUS #10 | 67 | F | 0.6 g/dL | IgG kappa | 5.56% |
| MGUS #11 | 56 | F | NQ; IgA, 464 mg/dL | IgA kappa | 6.00% |
NQ non-quantifiable
aThe participant whose pre-malignant plasma cells from the marrow were unable to be analyzed for the isotopomers of malate by GC-MS
bThe participant whose pre-malignant plasma cells from the marrow were unable to be analyzed for the isotopomers of glutamate by GC-MS
cThe participant who did not have sufficient pre-malignant plasma cells from the marrow to undergo RNA sequencing